NCT00078260CompletedPhase 3
A Randomized Phase 3 Study of Two Doses of Alimta in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed a Prior Platinum-Containing Chemotherapy
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 589
- Locations
- 1
- Primary Endpoint
- Overall survival
Study Overview
Brief Summary
The purposes of this study are to determine:
- the safety of pemetrexed and any side effects that might be associated with it
- how much pemetrexed should be given to patients.
It is possible that information collected during this study will be analyzed by the Sponsor in the future to evaluate pemetrexed for other possible uses or for other medical or scientific purposes other than those currently proposed.
Although pemetrexed has been shown to be effective in some patients with non-small-cell lung cancer, pemetrexed might not have beneficial effects for all patients.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Diagnosis of locally advanced or metastatic (Stage III or IV at entry) non-small cell lung cancer (NSCLC) that is not amenable to curative therapy.
- •Patients must have been previously treated with one platinum-containing chemotherapy regimen for locally advanced or metastatic disease. Patients are also eligible if they have received one platinum-based chemotherapy regimen as neoadjuvant or adjuvant chemotherapy, but must have received an additional chemotherapy regimen upon recurrence.
- •No more than two prior systemic anti-cancer therapies will be allowed.
- •Prior radiation therapy is allowed to less than 25% of the bone marrow. Prior radiation to the whole pelvis is not allowed. Prior radiotherapy must be completed at least 2 weeks before study enrollment, and the patient must have recovered from the acute toxic effects of the treatment prior to study enrollment.
Exclusion Criteria
- •Pregnancy.
- •Breast-feeding.
- •Second primary malignancy that is clinically detectable at the time of consideration for study enrollment.
- •Inability to interrupt aspirin, or other nonsteroidal anti-inflammatory agents for a 5-day period.
- •Inability or unwillingness to take folic acid or vitamin B12 supplementation.
Arms & Interventions
A
Experimental
Intervention: pemetrexed (Drug)
B
Experimental
Intervention: pemetrexed (Drug)
Outcomes
Primary Outcomes
Overall survival
Time Frame: baseline to date of death from any cause
Secondary Outcomes
- Progression free survival(baseline to measured progressive disease)
- Tumor response rate(baseline to measured progressive disease)
- Adverse events(every cycle)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
Pemetrexed as First Line Chemotherapy for Advanced Breast CancerBreast CancerNCT00065533Eli Lilly and Company92
Completed
Phase 2
A Study of Pemetrexed in Small Cell Lung Cancer, Which Has ReturnedCarcinoma, Small CellNCT00191750Eli Lilly and Company80
Completed
Phase 1
ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic CancerMetastasesCancerNCT00034463Eli Lilly and Company
Completed
Phase 3
Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)Non-small Cell Lung CancerNCT03515837Merck Sharp & Dohme LLC492
Completed
Phase 1
Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal CancerPrimary Peritoneal CancerOvarian CancerNCT00489359Eli Lilly and Company86